-
Mashup Score: 0April 2024: Notable Drug Approvals - 11 hour(s) ago
Notable drug approvals from April 2024.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0FDA Clears Stork OTC Baby Monitoring System - 15 hour(s) ago
The sensor is contained within the Stork boot, which is secured to the baby’s foot.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Ryplazim Available Again for Hypoplasminogenemia - 3 day(s) ago
Ryplazim is supplied in a 50mL single-dose vial containing 68.8mg of plasminogen as a lyophilized powder for intravenous use after reconstitution.
Source: www.empr.comCategories: General Medicine News, General Journals & SocietTweet
-
Mashup Score: 0Xolremdi Approved for Patients With WHIM Syndrome - 4 day(s) ago
The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 4WHILM trial.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0FDA Drug Approval Decisions Expected in June 2024 - 5 day(s) ago
The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0MPR Weekly Dose Podcast #200 - 6 day(s) ago
Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Distribution will end on June 1, 2024.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
Each Ingrezza Sprinkle capsule contains oral granules consisting of valbenazine, a vesicular monoamine transporter 2 inhibitor.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0MPR Weekly Dose Podcast #200 - 9 day(s) ago
Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Beqvez Approved as One-Time Gene Therapy for Hemophilia B - 13 day(s) ago
Beqvez is a one-time AAV-based gene therapy designed to introduce in the transduced cells a functional copy of the FIX gene encoding a high-activity FIX variant.
Source: www.empr.comCategories: General Medicine News, General HCPsTweet
At-a-glance recap of April's notable new drug approvals. https://t.co/omc6NhzSGr https://t.co/2AjNVTxZSy